These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 26596218)

  • 1. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
    Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
    Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
    Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
    Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
    Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
    Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
    Kato Y; Salumbides BC; Wang XF; Qian DZ; Williams S; Wei Y; Sanni TB; Atadja P; Pili R
    Mol Cancer Ther; 2007 Jan; 6(1):70-81. PubMed ID: 17237267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
    Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
    J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
    Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
    PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing and re-expression of retinoic acid receptor beta2 in human melanoma.
    Fan J; Eastham L; Varney ME; Hall A; Adkins NL; Chetel L; Sollars VE; Georgel P; Niles RM
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):419-29. PubMed ID: 20374520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of histone deacetylase 4, -5 and -6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin.
    Oya Y; Mondal A; Rawangkan A; Umsumarng S; Iida K; Watanabe T; Kanno M; Suzuki K; Li Z; Kagechika H; Shudo K; Fujiki H; Suganuma M
    J Nutr Biochem; 2017 Apr; 42():7-16. PubMed ID: 28103535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway.
    Lefebvre B; Brand C; Flajollet S; Lefebvre P
    Mol Endocrinol; 2006 Sep; 20(9):2109-21. PubMed ID: 16613989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
    Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
    Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
    Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
    Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
    Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation.
    Raif A; Marshall GM; Bell JL; Koach J; Tan O; D'andreti C; Thomas W; Sekyere E; Norris M; Haber M; Kavallaris M; Cheung BB
    Cancer Lett; 2009 May; 277(1):82-90. PubMed ID: 19147277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
    Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
    Dummer R; Beyer M; Hymes K; Epping MT; Bernards R; Steinhoff M; Sterry W; Kerl H; Heath K; Ahern JD; Hardwick JS; Garcia-Vargas J; Baumann K; Rizvi S; Frankel SR; Whittaker SJ; Assaf C
    Leuk Lymphoma; 2012 Aug; 53(8):1501-8. PubMed ID: 22239668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.